Institute of Cardiovascular Sciences, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University, Beijing 100191, China.
Hebei Invivo Biotech Co., Shijiazhuang, China.
Metabolism. 2018 Jun;83:245-255. doi: 10.1016/j.metabol.2018.03.003. Epub 2018 Mar 9.
Lecithin cholesterol acyltransferase (LCAT) plays a pivotal role in HDL metabolism but its influence on atherosclerosis remains controversial for decades both in animal and clinical studies. Because lack of cholesteryl ester transfer protein (CETP) is a major difference between murine and humans in lipoprotein metabolism, we aimed to create a novel Syrian Golden hamster model deficient in LCAT activity, which expresses endogenous CETP, to explore its metabolic features and particularly the influence of LCAT on the development of atherosclerosis.
CRISPR/CAS9 gene editing system was employed to generate mutant LCAT hamsters. The characteristics of lipid metabolism and the development of atherosclerosis in the mutant hamsters were investigated using various conventional methods in comparison with wild type control animals.
Hamsters lacking LCAT activity exhibited pro-atherogenic dyslipidemia as diminished high density lipoprotein (HDL) and ApoAI, hypertriglyceridemia, Chylomicron/VLDL accumulation and significantly increased ApoB100/48. Mechanistic study for hypertriglyceridemia revealed impaired LPL-mediated lipolysis and increased very low density lipoprotein (VLDL) secretion, with upregulation of hepatic genes involved in lipid synthesis and transport. The pro-atherogenic dyslipidemia in mutant hamsters was exacerbated after high fat diet feeding, ultimately leading to near a 3- and 5-fold increase in atherosclerotic lesions by aortic en face and sinus lesion quantitation, respectively.
Our findings demonstrate that LCAT deficiency in hamsters develops pro-atherogenic dyslipidemia and promotes atherosclerotic lesion formation.
卵磷脂胆固醇酰基转移酶(LCAT)在 HDL 代谢中起着关键作用,但在动物和临床研究中,其对动脉粥样硬化的影响几十年来一直存在争议。由于缺乏胆固醇酯转移蛋白(CETP)是脂蛋白代谢中鼠类和人类的主要区别,我们旨在创建一种新型叙利亚金黄仓鼠模型,该模型缺乏 LCAT 活性,但表达内源性 CETP,以探讨其代谢特征,特别是 LCAT 对动脉粥样硬化发展的影响。
使用 CRISPR/CAS9 基因编辑系统生成突变型 LCAT 仓鼠。通过与野生型对照动物进行各种常规方法比较,研究了突变型仓鼠的脂质代谢特征和动脉粥样硬化的发展。
缺乏 LCAT 活性的仓鼠表现出促动脉粥样硬化的血脂异常,表现为高密度脂蛋白(HDL)和 ApoAI 减少、高甘油三酯血症、乳糜微粒/极低密度脂蛋白(VLDL)积聚以及 ApoB100/48 显著增加。对高甘油三酯血症的机制研究表明,LPL 介导的脂肪分解受损,VLDL 分泌增加,涉及脂质合成和转运的肝脏基因上调。突变型仓鼠的促动脉粥样硬化血脂异常在高脂肪饮食喂养后加剧,最终导致主动脉正面和窦病变定量分析中动脉粥样硬化病变分别增加近 3 倍和 5 倍。
我们的研究结果表明,仓鼠 LCAT 缺乏可导致促动脉粥样硬化血脂异常,并促进动脉粥样硬化病变形成。